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Background: Deep-sequencing methods are rapidly developing in the field of B-cell receptor (BCR) and T-cell
receptor (TCR) diversity. These promise to revolutionise our understanding of adaptive immune dynamics, identify
novel antibodies, and allow monitoring of minimal residual disease. However, different methods for BCR and TCR
enrichment and amplification have been proposed. Here we perform the first systematic comparison between
different methods of enrichment, amplification and sequencing for generating BCR and TCR repertoires using large
sample numbers.
Results: Resampling from the same RNA or cDNA pool results in highly correlated and reproducible repertoires,
but resampling low frequency clones leads to stochastic variance. Repertoires generated by different sequencing
methods (454 Roche and Illumina MiSeq) and amplification methods (multiplex PCR, 5’ Rapid amplification of cDNA
ends (5’RACE), and RNA-capture) are highly correlated, and resulting IgHV gene frequencies between the different
methods were not significantly different. Read length has an impact on captured repertoire structure, and ultimately
full-length BCR sequences are most informative for repertoire analysis as diversity outside of the CDR is very useful
for phylogenetic analysis. Additionally, we show RNA-based BCR repertoires are more informative than using DNA.
Conclusions: Repertoires generated by different sequencing and amplification methods are consistent, but we
show that read lengths, depths and error profiles should be considered in experimental design, and multiple
sampling approaches could be employed to minimise stochastic sampling variation. This detailed investigation of
immune repertoire sequencing methods is essential for informing basic and clinical research.Background
The adaptive immune response selectively expands B-
and T-cell clones from a diverse antigen naïve repertoire
following antigen recognition by the hyper-variable re-
gions of B- or T-cell receptors (BCR and TCR) respec-
tively [1,2]. Functional BCRs and TCRs are generated by
site-specific recombination of V, (D), and J gene seg-
ments [3–5], with imprecise joining of the gene seg-
ments leading to random deletion and insertion of
nucleotides at the junctional regions. Clonal affinity
selection for enhanced BCR-antigen or TCR-peptide
binding contributes to shaping the mature immune
repertoire [6–8].* Correspondence: pk5@sanger.ac.uk
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article, unless otherwise stated.Mapping of BCR and TCR repertoires promises to
transform our understanding of adaptive immune dy-
namics, with applications ranging from identifying novel
antibodies and determining evolutionary pathways for
haematological malignancies to monitoring of minimal
residual disease following chemotherapy [1,2,8,9]. How-
ever, there is concern over the validity of biological insights
gained from the different BCR and TCR enrichment, amp-
lification and sequencing methods. With immune reper-
toire sequencing becoming an increasingly recognised and
important tool for understanding the adaptive immune
system, we have performed the first systematic comparison
between different isolation, amplification and sequencing
methods for elucidating B-cell repertoire diversity by deep
sequencing. We have used samples of diverse B-cell popu-
lations from healthy peripheral blood (PB), clonal B-cell
populations from lymphoblastoid cell lines (LCL) and PB
from chronic lymphocytic leukaemia (CLL) patients [9].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ferences between methods. Firstly, IgHV gene usage is
typically reported as an assessment of BCR repertoire
structure, where healthy individuals exhibit low frequen-
cies of most or all IgHV genes, and where clonal po-
pulations have significantly higher frequencies of a single
IgHV gene or group of IgHV genes [10]. We formally as-
sess whether there is differential or biased method-specific
amplification of each IgHV gene by comparing IgHV fre-
quencies observed between different methods applied to
each sample. Secondly, we compare the individual BCR
full-length sequence frequencies between different sam-
ples to assess the reproducibility of each BCR repertoire
method. Thirdly, the overall clonality of each sample can
be assessed and compared using previously published
clonality measures of vertex Gini indices, cluster Gini in-
dices and maximum cluster sizes using BCR sequence net-
work analysis [9]. Briefly, the Gini index is a measure of
unevenness. When applied to the vertex size distribution
for a given sample, the Gini index indicates the overall
clonal nature of a sample, and when applied to the cluster
size distribution, the Gini index indicates the overall som-
atic hypermutation in the sample. Low vertex Gini indices
represent diverse populations and high vertex Gini indices
represent clonal populations of B-cells. Similarly, low clus-
ter Gini indices represent populations with lower muta-
tional diversity and high cluster Gini indices represent
clonal populations with higher mutational diversity. The
maximum cluster size is the percentage of reads corre-
sponding to the largest cluster and indicates the degree of
clonal expansion of a sample. This allows assessment of
whether overall BCR repertoire structures are faithfully
retained between the different methods.
Methods
Samples
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from 10 ml of whole blood from 9 healthy vo-
lunteers and 8 CLL patients using Ficoll gradients (GE
Healthcare). Total RNA was isolated using TRIzol® (Invi-
trogen) and purified using RNeasy Mini Kit (Qiagen)
including on-column DNase digestion according to manu-
facturer’s instructions. Total RNA was also isolated from
1×106 cells from 10 human lymphoblastoid cell lines
(LCLs) from the HapMap project [11]. Research was ap-
proved by relevant institutional review boards and ethics
committees (07/MRE05/44, Eastern NHS Multi Research
Ethics Committee), and all subjects gave written con-
sent for the research [9]. Samples are summarised in
Additional file 1: Table S4.
RNA and DNA multiplex PCR amplification
Multiplex PCR amplification of RNA samples were per-
formed according to Bashford-Rogers et al. [9] (primersin Additional file 1: Table S3). For multiplex PCR ampli-
fication of DNA, 30 ng of DNA was mixed with the JH
reverse primer and the FR1 forward primer set (0.25 μM
each), using 0.5 μl Phusion® High-Fidelity DNA Poly-
merase (Finnzymes), 1 μl dNTPs (0.25 mM), 1 μl DTT
(0.25 mM), per 50 μl reaction. The following PCR pro-
gram was used: 3 minutes at 94°C, 35 cycles of 30 sec-
onds at 94°C, 30 seconds at 60°C and 1 minute at 72°C,
with a final extension cycle of 7 minutes at 72°C on an
MJ Thermocycler.
RNA-capture
Total RNA was initially processed for target enrichment
using the NEBNext kit (NEB) according to manufacturers
protocol. Briefly, mRNA was isolated by polyA + selection
and converted to cDNA. cDNA at 0.3 to 0.7 ng/μl was
fragmented to 200 bp (Covaris), ligated to sequencing
adaptors (Illumina) and size selected at 200 bp (Life Tech-
nologies E-Gel). Samples were then indexed for pre-
capture pooling (NEBNext Multiplex Oligos for Illumina
Index Primers 1 to 12). A pre-capture library was gene-
rated using 12 cycles of PCR (KAPA Biosystems Library
Amplification Kit). Libraries were pooled and hybridised
to biotinylated RNA-capture baits (custom design [12],
full protocol available on request), Agilent SureSelect) at
65°C for 24 h. Hybridised fragments were selected using
streptavidin magnetic beads, washed and eluted for multi-
plexed sequencing on Illumina Miseq.
5’RACE
5’RACE was performed using SMARTer™ Pico PCR
cDNA Synthesis Kit (Clontech) according to Clontech
protocols, using the JH-reverse primer (Additional file 1:
Table S3) and SMARTer 5’ primer for PCR amplification.
Sequencing methods and read preparation
Sequencing libraries were prepared using standard Roche-
454 Rapid Prep or Illumina protocols, and sequenced
using an FLX Titanium Genome Sequencer (Roche/454
Life Sciences) or by 250 bp paired-ended MiSeq (Illumina)
respectively. Raw 454 or MiSeq reads were filtered for
base quality (median Phred score >32) using the QUASR
program. (http://sourceforge.net/projects/quasr/) [13].
The 250 bp reads from the 5’RACE experiment were
retained if they contained a JH-reverse primer se-
quence and orientated to begin with IgHV gene. Non-
immunoglobulin sequences were removed and only reads
with significant similarity to reference IgHV genes from
the IMGT database [14] using BLAST [15] were re-
tained (1×10−10 E-value threshold). Primer sequences
were trimmed from the reads, and sequences retained
for analysis only if both primer sequences were iden-
tified. Reads from RNA-capture were BLAST aligned to
reference IgH genes, and trimmed if the reads extended
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were filtered for length (>255 bp, 120 bp and 160 bp for
454, MiSeq (250 bp paired-end) and RNA-capture MiSeq
respectively). The combined per-base error-rate for the
RT-PCR and sequencing process for the 454 and MiSeq
platforms were similar to other studies (1.74x10−4 and
2.06×10−4 respectively) [9,10,16]. Excluding homopoly-
meric indels, the per-base error rate for 454 is 7.04×10−5.
Repertoire analysis
For identification of IgHV genes, BLAST [15] was used
to align the BCR sequences against known BCR se-
quences from the ImMunoGeneTics (IMGT) database
[14] (e-value threshold of 10−20). Network assemblies
and diversity measure calculations (vertex Gini index,
cluster Gini index and maximum cluster size) were per-
formed according to Bashford-Rogers et al. [9]. Statis-
tical analyses were performed in R. Differences between
454 sequence sets excluded homopolymeric indels.
Simulation of sampling BCR populations
For a given sequencing depth N, the range of values, x,
within 10% of the true BCR proportion pi would be
blower≤x ≤bupper
Where blower =N * pi * 0.9 blower =N * pi * 0.9 and
bupper =N * pi * 1.1, and 0 ≤ blower, bupper ≤N. With a se-
quencing error rate e per base, the probability of suc-
cessfully sequencing the BCR sequence of length l
becomes p = pi − (e * l). Therefore the probability of sam-
pling within the range x is the sum of the binomial
probabilities of the range x:






pi 1− pð ÞN−i
To estimate the probability of sequencing at least one
read of a given type, the Poisson distribution can be
employed:
P X ≠ 0ð Þ ¼ 1− e−λ
Where λ is the expected value of sequencing reads of
that type, λ =N * p.
Results and discussion
Assessing the stochasticity of sampling B-cell repertoires
As exhaustive sampling of B-cells is not possible in
humans, the “true” extent of the BCR repertoire in hu-
mans can only be estimated. A typical PB sample (10-
20 ml) accounts for ~0.2% of the total PB, from which
only a fraction is used in current BCR sequencing me-
thods. Therefore, we examined the effect of resampling
on repertoire structure. Firstly, we repeated repertoiresequencing of the same multiplex PCR products from
10 LCL and 5 healthy PB samples using 454 sequencing
(Figure 1A, sequencing repeat). Comparing frequency dis-
tributions for each IgHV gene formally assesses differential
representation of particular IgHV genes. The IgHV fre-
quencies are highly correlated between repeats with a gra-
dient close to unitary (Figure 1B, R2-value = 0.9998, y =
1.002×, unitary gradient equals a one-to-one mapping be-
tween repeats) even at low IgHV frequencies (Figure 1C),
suggesting minimal stochasticity introduced through se-
quencing alone.
Next, we determined the stochastic variation observed
when re-sampling 2 equimolar portions of the same
RNA from 9 CLL PB samples, and repeating both PCR
and MiSeq sequencing (300 bp paired-end, Figure 1A,
RT-PCR repeats). The IgHV frequencies were again highly
correlated (R2-value = 0.9909, y = 1.115x, Figure 1D). The
correlation is lower than the sequencing repeats suggest-
ing greater re-sampling stochasticity introduced at the
PCR steps. As the correlation might be skewed by the very
high clonality of the CLL samples, the expected corre-
lation between experimental conditions using diverse sam-
ples is best assessed from low frequency gene usage,
shown in Figure 1E. As expected, the correlation between
IgHV genes present at low frequencies (<15%, represen-
ting frequencies typically observed in diverse B-cell sam-
ples) is less than that of IgHVs present at higher frequency
reflecting lower probabilities of re-sampling rarer mole-
cules (R2-value = 0.8815 for RT-PCR repeats, Figure 1E),
which is in-line with previous studies [9].
We also used clonality measures, Gini index and ma-
ximum cluster size, and individual BCR sequence fre-
quencies to determine whether overall BCR repertoire
structures were faithfully retained between the repeats
[9]. These diversity measures correspond to that seen in
equivalent sample types in previous studies (Table 1,
[9]). These repertoire diversity measures are strongly
correlated between both sequencing and RT-PCR repeats
(Additional file 1: Figure S2 A-B, R2-values > 0.991). We
show that the correlation between the individual BCR fre-
quencies between RT-PCR repeats is strong (R2 = 0.9793),
although again the correlation is weaker when consid-
ering only the low frequency BCRs (Additional file 1:
Figure S2 C). Therefore, samples from the same RNA
pool exhibit some re-sampling stochasticity, particu-
larly for low frequency variants. However, overall re-
peated samples are highly correlated and repertoires are
reproducible.
Assessing differences between sequencing methods
Different sequencing platforms each have different read-
lengths, depths and error profiles (Additional file 1:
Tables S1-2). 454 sequencing uses emulsion PCR and
pyrosequencing and can produce reads potentially over
Figure 1 Comparing different RNA-capture and amplification methods. A) Schematic diagram of all experiments. Left side: RNA was
extracted from B-cell samples, and multiplex RT-PCR performed in triplicate: sequencing repeats (re-sequencing the same PCR products), PCR
repeats (independent RT-PCR of the same RNA and sequencing by MiSeq) and sequencing method comparisons (independent RT-PCR of the
same RNA source and sequenced by 454 and MiSeq). Right side: RNA was extracted from B-cell samples, and 5’RACE (by MiSeq), RNA-capture (by
MiSeq) were compared to PCR amplification of the same samples (using 454 sequencing). Graphs of IgHV gene-usage frequency distributions
between samples were generated from B) the sequencing repeats, D) RT-PCR repeats, F) sequencing method comparisons, H) multiplex PCR
versus 5’RACE (by MiSeq), J) multiplex PCR versus RNA-capture (sequenced by MiSeq). Graphs C, E, G, I and K) are IgHV gene-usage frequency
distributions from only the low frequencies (<15%) respectively. Point colors are red, blue and green for healthy, LCL and CLL samples
respectively. The linear regression equation and R2-values are given. L) Plot of the probability of sampling within 10% of the true of a
BCR proportion with varying read depths (10,000, 25,000, 100,000, 1,000,000 and 10,000,000 reads) assuming an initial population of
50,000,000 BCR sequences after amplification.
Table 1 Mean diversity measures for each sample type
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full BCR amplicon in a single read. However, the 454 plat-
form has high homopolymeric base pair error-rates caused
by accumulated light intensity variance [16,18–20]. The
Illumina MiSeq has the highest throughput per run (1.6
Gb of sequence/run, 60 Mb/hour) [17] and lower overall
error rate, particularly in homopolymeric regions [21].
MiSeq however has its own distinct error profile of single-
base errors associated with GGC motif [22] and at the 3’
end of the reads compared to the 5’ end. MiSeq can cur-
rently generate up to 300 bp paired-end reads that allows
for paired-end joining and full coverage of multiplex PCR
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ing two portions of RNA from 8 CLL and 6 healthy PB
samples and performed PCR followed by 454 or MiSeq
(250 bp paired-end) sequencing (Figure 1A, sequencing
comparison). The IgHV frequencies between the sequen-
cing methods were highly correlated (R2-value = 0.9844,
y = 0.998x, Figure 1F). As the correlation might be skewed
by the very high clonality of the CLL samples, we assessed
the correlation at low frequency gene usages. Again,
greater variation of low frequency variants suggests both
effects of stochastic re-sampling and platform-specific dif-
ferences (gene frequencies <15% representing typical ob-
servations from diverse B-cell samples, Figure 1G, R2-
value = 0.5885). The individual BCR sequence frequencies
were also highly correlated (Additional file 1: Figure S3A),
suggesting that repertoire structure is retained when using
the same amplification method on different sequencing
platforms. However, due to the lower homopolymeric
indel rate, only the MiSeq platform is currently appro-
priate for filtering read sets for open reading frames (and
subsequent translation into protein sequence). MiSeq also
has the advantage of a higher sequencing depth per lane,
therefore allowing higher levels of multiplexing of samples
and reducing the per-sample cost.
How deep do we need to sequence?
The sequencing depth required depends on the frequen-
cies of clones of interest and sequencing method. Reads
from all methods were filtered for quality and presence
of immunoglobulin sequence as detailed in the methods
section. Here, the percentage of filtered BCR sequences
from PCR amplification was 60% and 76% for MiSeq
and 454 sequencing respectively and 55% for 5’RACE
(using MiSeq). As the RNA-capture baits target both
BCRs and TCRs, the percentage of usable BCR sequen-
ces was only 1.53% (Additional file 1: Table S2). There-
fore, between 35-50x higher sequencing depth is required
for RNA-capture to obtain the equivalent number of
BCR-specific reads compared to the other methods. To
determine the number of BCR sequences required for bio-
logical studies, we modelled the probabilities of sequen-
cing BCR clones at varying BCR sampling proportions
and sequencing depths. Assuming an initial population of
50,000,000 BCRs after amplification, when a BCR clone
is >4% of the total population, a sequencing depth of
only 10,000 reads has a 95% probability of sequencing
within 90% accuracy (i.e. within 10% of the true clonal
proportion, Figure 1L). For rarer BCR clones, higher se-
quencing depths can significantly increase sampling accur-
acy. For example, the probability of sequencing within
90% accuracy for a clone at 0.04% of the total population
is increased from 0.522 at 100,000 reads to 0.956 at
1,000,000 reads (i.e. 1/10 lane of MiSeq). For clones
of <0.001%, increasing the sequencing depth to as high as1×107 does not significantly increase sequencing accuracy
due to low re-sampling probabilities. Thus, the optimum
sequencing depth depends on the samples used and bio-
logical question. Studies investigating highly clonal disor-
ders, such as CLL, require less reads to obtain information
about clonal sequence than studies of healthy individuals
with diverse repertoires of low frequency clones.
Assessing different RNA-capture and amplification
methods
The three main BCR amplification methods are PCR
using IgH-specific multiplex primers [23], 5’ Rapid
amplification of cDNA ends (5’RACE) [24–27] and RNA-
capture using RNA bait/capture probes [28,29]. IgH-
specific multiplex PCR primers have been designed [23],
validated [30–34], and used in numerous biological stud-
ies [9,10,35–41]. Such multiplex PCRs can be performed
on either RNA or DNA and require a relatively small
amount of template. However, there is the potential for
biased primer annealing and unequal PCR amplification
of BCR sequences. RNA-capture is based around the me-
thods used for human exome sequencing and uses RNA
bait/capture probes and subsequent universal PCR ampli-
fication [28,29]. This allows for enrichment, amplification
and sequencing of TCRs (α, β, γ and δ chains) and BCRs
(heavy and light chains) simultaneously. PCR and RNA-
capture methods can use RNA or DNA, but have the
potential for sequence-based differential annealing and
biased capture. 5’RACE overcomes this by using a single
IgH-specific primer for first strand Ig cDNA synthesis and
subsequent sequence-independent template switching
primer for second strand cDNA synthesis. This elimi-
nates potential multiplex primer bias, but can have low
efficiency, high non-specific amplification, and short frag-
ment contamination from RNA degradation or incom-
plete cDNA synthesis and template switching [24–27].
Also, as the RNA bait probes and multiplex PCR primers
are generated from reference Ig and TCR gene databases,
they lack the same efficiency as 5’RACE for capturing hu-
man allelic variants of TCR or BCR segments that are not
represented in the reference database.
To compare the different amplification methods, 5’RACE
(with MiSeq sequencing) was performed on 7 CLL and 5
healthy PB samples, RNA-capture (with MiSeq sequen-
cing) was performed on 1 healthy and 1 CLL PB, and were
compared to multiplex PCR of the same samples (using
454 sequencing, Figure 1A). Strong IgHV gene frequency
correlations were observed between PCR and 5’RACE
(R2-value = 0.9792), and between PCR and RNA-capture
(R2-value = 0.9795) (Figures 1H-K). This correlation is
again weaker for lower frequency BCR sequences (R2-
value = 0.6041 and 0.8811 respectively, Figures 1I and K).
Comparing individual BCR sequences rather than IgHV
gene frequencies showed strong correlations between all
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above 5% BCR sequence frequency. Both Pairwise-
Wilcoxon tests and paired T-tests between IgHV gene
frequencies (with Bonferroni multiple-testing corrections)
showed no significant differentially captured IgHV genes
between the RNA-capture, 5’RACE or PCR methods. To-
gether, we suggest each method here captures similar BCR
repertoires.
Effect of amplicon length
Shorter amplicons give less phylogenetic information
and mutational pathways of B-cell clones may be lost,
thus artificially separating related BCRs into different
clusters. Within B-cell networks different BCR sequen-
ces can be reduced into the same vertex if the mutations
are located outside the read, so clusters have lower num-
bers of vertices. Therefore, we compared the impact of
using different length amplicons on the diversity of the
generated BCR repertoire. The PCR sequencing reads
were trimmed to represent three regions of the IgH mol-
ecule: i) sequences containing bases within 250 bp from
the end of the IgHJ region (mimicking reads from the
5’RACE experiment), ii) sequences covering the most
variable part of the IgH molecule, the complementarity-
determining region 3 (CDR3), that is often the focus of
biological studies, such as [42,43], or iii) the mean region
covered by reads from RNA-capture (~170 bp, bet-
ween ~115 bp from the IgHV 3’ end and ~30 bp from the
IgHJ 5’ end)), (Figure 2A and Additional file 1: Figure S4).
The corresponding BCR sequence networks were gener-
ated. The number of unique BCR sequences per sample
reduced significantly from 10847 using the full-length
PCR reads to 9555, 8041, 8974 using 5’RACE-equivalent,Figure 2 Variation of diversity measures with read-length. A) Schemat
against the BCR gene. 454 multiplex sequencing reads were trimmed eithe
region, ii) CDR3 region, iii) or the mean region covered by reads from the R
of IgHJ), and corresponding BCR networks were generated. Plots show the
Index. Point colors are red, green and blue for healthy PBMC, LCL and CLLCDR3 and RNA-capture read-lengths respectively
(p-values < 0.005, Figure 2B). The diversity of the resulting
networks using cluster Gini indices show significant devi-
ation from the full-length PCR reads (Figure 2C, visualized
in Additional file 1: Figure S5). Using sequencing plat-
forms with shorter read lengths, e.g. Illumina with less
than 250 bp reads also lower the potential to capture IgH
genetic diversity, thus reducing repertoire information.
The diversity outside of CDR3 is very useful to capture for
phylogenetic analysis and ultimately the full-length BCR
sequence (obtainable from 300 bp paired-ended MiSeq
reads or by 454 sequencing) is most informative for reper-
toire analysis.
RNA versus DNA: which is best for BCR sequencing?
PCR and MiSeq (250 bp, paired-end) sequencing was
performed on both RNA and DNA fractions from 8 CLL
patients’ PB to compare the effect of input material. First
BCR allele defective-rearrangements present in the gen-
omic DNA have the potential to artificially increase the
number of clones in the data [44], whereas unequal
numbers of RNA molecules per cell may skew the BCR
repertoires derived from RNA. An average of 71.2% of
reads from the DNA repertoire were represented at least
once in the RNA repertoire (range 28.1-94.9%, Figure 3A).
Sequences found in both RNA and DNA repertoires are
likely to be functional BCR sequences, whereas DNA se-
quences not observed in the RNA repertoire could either
be non-functional by the process of “allelic-exclusion”, or
due to the lack of re-sampling. The frequencies of individ-
ual BCR sequences from RNA compared to the functional
DNA reads (i.e. DNA reads found in the RNA reper-
toire) are strongly correlated (R2-value = 0.9999, y = 0.988x)ic diagram showing the read-lengths from each technique aligned
r between i) containing bases within 250 bp from the end of the IgHJ
NA-capture method (149 bp from 3’end of IgHV to 41 bp from 5’end
variation of B) number of unique sequencing reads and C) Cluster Gini
samples respectively.
Figure 3 Comparison of RNA and DNA repertoires. RNA and DNA were extracted from each peripheral blood sample from 8 CLL patients, on
which multiplex RT-PCR or PCR was performed respectively and sequenced by MiSeq (250 bp paired-end). A) The percentage of DNA sequences
found in each RNA sample. The correlation between the BCR frequency in RNA and functional DNA repertoires (DNA sequences that were found
also in the RNA repertoire) for the 8 CLL patients in B) all IgHV gene usage frequencies and C) the low frequency IgHV gene usage frequencies
only (<2%). If unequal numbers of RNA molecules per cell significantly skewed the RNA BCR repertoires, then deviation from y = x correlation
would be expected.
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RNA proportions, even at low frequencies (Figure 3B-C).
Therefore, due to defective-rearrangements present in the
genomic DNA, RNA is potentially more informative than
DNA for understanding BCR population structures.
Conclusions
Next-generation sequencing of immune receptor genes
can provide a quantitative understanding of the land-
scape of the adaptive immune response. The “true” BCR
repertoire in humans is not known, and current methods
rely on taking small samples of the total B-cells to esti-
mate the population structure. Here we show little sam-
pling bias in repeat samples and that multiplex PCR,
RNA-capture and 5’RACE each captures a similar over-
all BCR repertoire and clonal features of each sample.
RNA capture offers the advantage of capturing both B
and T-cell repertoires. We show that there is no signifi-
cant inflation or deflation of clonality due to unequal
numbers of RNA transcripts per cell and suggest that
using RNA input is more informative for understanding
B-cell population structure as genomic DNA potentially
exhibits artificially increased numbers of clones reflecting
biallelic rearrangements in a single clone [44]. Choice of
sequencing platform does not significantly affect the rep-
ertoire structure captured but an amplicon and sequence
reads covering the entire BCR is most informative for ana-
lysis and sequencing depth should be sufficient to allow
capture of the BCR frequency of interest. The ability to
detect BCR repertoire diversity and sensitivity varies with
read length and depth respectively, resulting in an ideal
BCR sequencing solution of amplification of the full VDJregion to a depth of 1,000,000 to identify unique BCRs at
0.04% frequency with 90% theoretical accuracy.
We show that the repertoires generated by different
sequencing and amplification methods is robust but read
lengths, depths and error profiles should be considered
in experimental design and multiple sampling approa-
ches could be employed to minimise stochastic sampling
issues. We consider the multiplex PCR method to be the
most automatable and sensitive method, with consist-
ently good amplification from samples with low numbers
of B-cells. The number of PCR cycles can be tailored to
the requirement of DNA amount required for sequen-
cing, and therefore the best method for large studies or
using samples with low cell numbers. We recommend
the use of 5’RACE if a sample is likely to be highly
somatically mutated, thus potentially modifying the an-
nealing sites for the multiplex PCR or RNA capture.
However, we have shown that in CLL, where there is on-
going somatic hypermutation, we see no evidence of dif-
ferential primer annealing ability. RNA-capture can be
useful for situations where both the B- and T-cell reper-
toires are to be assessed simultaneously. For sequencing,
we recommend MiSeq as it is able to produce high qual-
ity reads covering the full BCR, with read depths allow-
ing for sequencing of many samples on a single run by
multiplexing.Additional file
Additional file 1: Supplementary information. Description of data:
Supplemental data file.
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